Aura Biosciences (AURA) to Release Earnings on Monday

Aura Biosciences (NASDAQ:AURA) will likely be releasing its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Aura Biosciences to post earnings of ($0.43) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Aura Biosciences Stock Performance

AURA traded up $0.83 during trading on Monday, reaching $6.77. 290,169 shares of the company traded hands, compared to its average volume of 214,276. The company has a market cap of $429.85 million, a P/E ratio of -3.49 and a beta of 0.45. Aura Biosciences has a 12-month low of $4.34 and a 12-month high of $7.73. The firm has a fifty day simple moving average of $5.54 and a 200 day simple moving average of $5.85.

Insider Activity

In related news, insider Janet Jill Hopkins sold 20,401 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total transaction of $103,229.06. Following the sale, the insider owned 232,284 shares of the company’s stock, valued at $1,175,357.04. This represents a 8.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Amy Elazzouzi sold 8,549 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total transaction of $43,257.94. Following the transaction, the senior vice president owned 75,532 shares of the company’s stock, valued at $382,191.92. This trade represents a 10.17% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 123,076 shares of company stock worth $618,783. 6.30% of the stock is owned by corporate insiders.

Institutional Trading of Aura Biosciences

Several hedge funds have recently made changes to their positions in AURA. Trexquant Investment LP purchased a new position in Aura Biosciences in the fourth quarter worth about $234,000. Bank of America Corp DE raised its position in Aura Biosciences by 41.2% during the third quarter. Bank of America Corp DE now owns 36,183 shares of the company’s stock valued at $224,000 after purchasing an additional 10,550 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Aura Biosciences by 138.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 32,210 shares of the company’s stock valued at $199,000 after purchasing an additional 18,711 shares during the last quarter. Gallagher Fiduciary Advisors LLC bought a new stake in shares of Aura Biosciences in the 2nd quarter valued at approximately $189,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Aura Biosciences by 12.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,557 shares of the company’s stock worth $152,000 after purchasing an additional 2,693 shares during the period. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on AURA shares. Evercore began coverage on shares of Aura Biosciences in a research report on Tuesday, November 25th. They set an “outperform” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $20.50.

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.